Welcome to our dedicated page for Medtronic news (Ticker: MDT), a resource for investors and traders seeking the latest updates and insights on Medtronic stock.
Medtronic plc (NYSE: MDT) is a Galway, Ireland-based healthcare technology company whose news flow reflects its broad activity in medical devices, diabetes technology, surgical robotics, and cardiovascular therapies. Company announcements frequently highlight regulatory milestones, clinical evidence, product launches, capital markets activity, and corporate governance developments that matter to investors and healthcare professionals following MDT stock.
Recent news has featured U.S. Food and Drug Administration clearances for key technologies, including the Hugo robotic-assisted surgery (RAS) system for urologic procedures and the MiniMed Go Smart Multiple Daily Injection (MDI) system, which connects the InPen smart insulin pen and the Instinct sensor made by Abbott through the MiniMed Go app. Medtronic has also reported on the broad U.S. commercial launch of the MiniMed 780G automated insulin delivery system integrated with the Instinct sensor, expanding its diabetes technology ecosystem.
Investors can also track Medtronic’s cardiovascular and hypertension-related developments, such as the final National Coverage Determination from the U.S. Centers for Medicare & Medicaid Services for the Symplicity Spyral renal denervation system, and updates on growth drivers like pulsed field ablation and other cardiovascular therapies discussed in earnings releases. Financial news includes quarterly earnings reports, guidance updates, dividend declarations, and details of senior notes offerings and redemptions.
This MDT news page aggregates coverage of topics including diabetes business developments (such as the planned MiniMed IPO registration), conference presentations, leadership and board changes, and major clinical or reimbursement milestones. Readers interested in Medtronic’s role in chronic disease management, minimally invasive surgery, and global healthcare technology can use this page to follow ongoing announcements and review the company’s evolving strategic priorities over time.
Medtronic plc (NYSE:MDT) will report its financial results for the first quarter of fiscal year 2022 on August 24, 2021, at 5:45 a.m. CDT. This announcement follows the quarter ending on July 30, 2021. A video webcast discussing the results will be held the same day at 7:00 a.m. CDT. The company also plans to report future quarterly results on November 23, 2021, February 22, 2022, and May 26, 2022. For further details, access Medtronic's newsroom.
Medtronic has announced a definitive agreement to acquire Intersect ENT for $28.25 per share in an all-cash deal, totaling approximately $1.1 billion. This acquisition aims to enhance Medtronic's portfolio in ear, nose, and throat procedures. Intersect's products, including the PROPEL® and SINUVA® implants, will complement Medtronic's existing offerings, facilitating better treatment for patients with chronic rhinosinusitis (CRS). The deal is expected to close by the end of Medtronic's fiscal year, pending regulatory approvals and stockholder consent.
Summary not available.
Medtronic plc (NYSE: MDT) has received FDA clearance for two AccuRhythm AI algorithms to enhance the LINQ II insertable cardiac monitor's diagnostic accuracy. These algorithms focus on reducing false alerts for atrial fibrillation and asystole, achieving significant improvements with a 74.1% reduction in false AF alerts and a 97.4% reduction in false pause alerts. The algorithms will be available on the CareLink Network later this year. This innovation is expected to support better patient management and improve clinical efficiencies for healthcare providers.
Medtronic plc (NYSE: MDT) released data from the WRAP-IT study, showing an 82% reduction in major infections for patients with hematomas following cardiac implants when using the TYRX Absorbable Antibacterial Envelope. The study involved 6,800 patients, highlighting a 2.2% hematoma incidence consistent across groups. The findings indicate that hematomas significantly increase infection risks, with implications for 1.5 million annual CIED recipients worldwide. Medtronic aims to mitigate these risks through the envelope, which is designed to release antibacterial agents and stabilize devices post-implantation.
Medtronic has launched the Prevail™ drug-coated balloon (DCB) catheter in Europe following CE mark approval. Designed for treating complex coronary lesions during percutaneous coronary interventions, the Prevail DCB features rapid absorption of paclitaxel and superior deliverability. Clinical results from the PREVAIL Study showed favorable late loss of 0.05 ± 0.44 mm at 6 months and a strong safety profile, with no stent thrombosis or cardiac death. This device builds on the previous IN.PACT Falcon DCB, addressing the challenges of complex vessels in interventional cardiology.
Medtronic (NYSE:MDT) has integrated the Hugo robotic-assisted surgery system at Hospital Clinico de la Red de Salud UC CHRISTUS in Santiago, Chile, enhancing access to minimally invasive procedures. This partnership marks a significant step in Medtronic's Partners in Possibility Program. The system aims to address cost barriers and improve surgical outcomes, as currently, only 3% of surgeries utilize robotic assistance globally. Additionally, a new Surgical Robotics Experience Center has opened in Santiago for clinician training. The Hugo RAS system is not yet cleared in the U.S. or Europe.
Medtronic plc (NYSE:MDT) announced an economic model based on the PRODIGY trial, demonstrating that continuous pulse oximetry and capnography monitoring can save over $500,000 annually for hospitals. This model predicts a reduction in respiratory depression by 20%, leading to a decrease of 103 patient days per year in a median-sized U.S. hospital. The findings emphasize the heightened safety and cost-effectiveness of continuous monitoring for patients receiving opioids compared to intermittent methods, supporting the company's commitment to improving patient outcomes.
Medtronic (NYSE:MDT) has launched the DEFINE AFib study, the first app-based research initiative aimed at understanding atrial fibrillation (AF) burdens and their effects on patient outcomes. Enrolling around 5,000 patients, the study utilizes data from the LINQ insertable cardiac monitors and the Medtronic Discovery App™. This remote study will enhance AF management through a machine learning approach, leveraging both device data and patient-reported information. Conducted with leading medical centers, it aims to personalize AF management strategies.
Medtronic plc (NYSE:MDT) presented significant clinical data at the American Diabetes Association's 81st Scientific Sessions, showcasing the InPen smart insulin pen and an extended-wear infusion set. Results indicated a 2.3% and 5% increase in Time in Range for users with glycemic management indicators over 8% and 9.5%, respectively, with no rise in hypoglycemia. Additionally, a study on the seven-day infusion set demonstrated sustained insulin delivery without severe adverse events. Both innovations aim to enhance diabetes management and patient experience.